A mid-stage trial of Roche Holding AG’s experimental immunotherapy showed that it doubled the likelihood of survival for lung cancer patients with the highest levels of a specific biomarker. The drug, known by the code name MPDL3280A, is part of a new class designed to help the body’s immune system fend off cancer by blocking […]

NEW HAVEN, Conn., May 13, 2015 /PRNewswire/ — LCS Group, LLC announced today its exclusive license from Lucerne Biosciences, LLC to commercialize U.S. Patent No. 8,318,813 and U.S. Patent Application No. 14/464,249, both titled “Method of Treating Binge Eating Disorder” (“BED”).   LCS Group’s exclusive license is part of a unique strategic collaboration with the intellectual property’s […]

Update 7:15: Click here for Orexigen’s comments on this situation. A top cardiologist is accusing a drug maker with whom he worked closely of making misleading statements about its weight loss medicine and refusing to release data that would undermine its previous claims. The pill, Contrave, was prescribed 117,000 times in its first three months on […]

With the drug industry launching more expensive targeted therapies, the number of Americans with annual medication costs of more than $50,000 has jumped more than 60% to nearly 600,000, a new analysis shows. The latest drug spending trend report from pharmacy benefit manager Express Scripts (ESRX) shows 576,000 Americans with annual medication costs of $50,000 […]

Two months ago, the biotechnology company Orexigen filed a patent claiming its weight-loss drug Contrave might prevent heart attacks based on the first 25% of data from an ongoing study. But the disclosure was improper, yielding protests from Steven Nissen, the Cleveland Clinic scientist running the study, Orexigen’s marketing partner, the Japanese drug giant Takeda, […]

Deerfield, Ill.-based Baxter International (BAX) said Tuesday it would buy a promising leukemia treatment, Oncaspar, from Italian company Sigma-Tau Finanziaria S.p.A. for $900 million, as it bolsters its oncology pipeline in an increasingly lucrative and competitive field. Baxter estimated oncology alone could bring in $10 billion once its pipeline is established, with Oncaspar already raking […]

A U.S. Food and Drug Administration advisory committee on Tuesday recommended approval of Vertex Pharmaceuticals Inc’s combination cystic fibrosis therapy, finding it to be safe and effective for patients ages 12 and up. The recommendation, which came in a 12-1 vote, will now be considered by FDA officials who are expected to decide by July […]

A person holds pharmaceutical tablets and capsules in this picture illustration taken in Ljubljana September 18, 2013. Reuters/Srdjan Zivulovic Almost two-thirds of the drug combinations widely sold in India to fight pain, depression, and psychotic conditions lack the necessary regulatory approvals, despite some of the pills being banned internationally, a study published on Tuesday shows. […]

Orexigen Therapeutics Inc and its partner Takeda Pharmaceutical Co said they were terminating a trial assessing the cardiovascular safety of obesity drug, Contrave. Orexigen Therapeutics shares were down 12.5 percent in after market trading after falling 13.6 percent in regular trading on the Nasdaq on Tuesday. The study was not being terminated due to the […]

A trial assessing the cardiovascular safety of obesity drug Contrave, made by Orexigen Therapeutics Inc and Takeda Pharmaceutical Co Ltd, was terminated on Tuesday due to unauthorized release of study data. A statement from Cleveland Clinic, which was conducting the trial, said the study was being halted as unauthorized release of trial data by Orexigen […]